Literature DB >> 21327584

Treatment of Aortoiliac Occlusive Disease: Medical versus Endovascular versus Surgical Therapy.

Mireille Astrid Moise1, Vikram S Kashyap.   

Abstract

OPINION STATEMENT: Aortoiliac occlusive disease (AIOD) is an insidious, progressive atherosclerotic process that can lead to claudication, rest pain, tissue loss, and eventual lower extremity amputation. The patient with AIOD is also at risk for both fatal and nonfatal cardiovascular events. Treatment of the disease includes both risk factor modification and efforts to improve blood flow to the lower extremity. For mild to moderate intermittent claudication, medical therapy as well as a supervised exercise program is advised. For debilitating claudication or critical limb ischemia, a number of recent studies support an endovascular approach for patients with AIOD, citing patency rates that compare favorably to open surgery. Surgical revascularization, however, should still be considered in selected patients.

Entities:  

Year:  2011        PMID: 21327584     DOI: 10.1007/s11936-011-0117-x

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  46 in total

1.  Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study.

Authors:  Joanne M Murabito; Jane C Evans; Kenneth Nieto; Martin G Larson; Daniel Levy; Peter W f Wilson
Journal:  Am Heart J       Date:  2002-06       Impact factor: 4.749

2.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

Review 3.  Supervised exercise therapy versus non-supervised exercise therapy for intermittent claudication.

Authors:  B L W Bendermacher; E M Willigendael; J A W Teijink; M H Prins
Journal:  Cochrane Database Syst Rev       Date:  2006-04-19

Review 4.  Review of direct anatomical open surgical management of atherosclerotic aorto-iliac occlusive disease.

Authors:  K W H Chiu; R S M Davies; P G Nightingale; A W Bradbury; D J Adam
Journal:  Eur J Vasc Endovasc Surg       Date:  2010-03-20       Impact factor: 7.069

5.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

6.  A contemporary comparison of aortofemoral bypass and aortoiliac stenting in the treatment of aortoiliac occlusive disease.

Authors:  Christopher R Burke; Peter K Henke; Roland Hernandez; John E Rectenwald; Venkat Krishnamurthy; Michael J Englesbe; James J Kubus; Guillermo A Escobar; Gilbert R Upchurch; Jonathan L Eliason
Journal:  Ann Vasc Surg       Date:  2010-01       Impact factor: 1.466

7.  Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000.

Authors:  Elizabeth Selvin; Thomas P Erlinger
Journal:  Circulation       Date:  2004-07-19       Impact factor: 29.690

8.  Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials.

Authors:  Jeffrey S Berger; Mori J Krantz; John M Kittelson; William R Hiatt
Journal:  JAMA       Date:  2009-05-13       Impact factor: 56.272

9.  Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.

Authors:  Sonia Anand; Salim Yusuf; Changchun Xie; Janice Pogue; John Eikelboom; Andrzej Budaj; Bruce Sussex; Lisheng Liu; Randy Guzman; Claudio Cina; Richard Crowell; Matyas Keltai; Gilbert Gosselin
Journal:  N Engl J Med       Date:  2007-07-19       Impact factor: 91.245

10.  Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions.

Authors: 
Journal:  J Vasc Surg       Date:  2007-04       Impact factor: 4.268

View more
  2 in total

1.  AG490 suppresses EPO-mediated activation of JAK2-STAT but enhances blood flow recovery in rats with critical limb ischemia.

Authors:  Han-Tan Chai; Hon-Kan Yip; Cheuk-Kwan Sun; Shu-Yuan Hsu; Steve Leu
Journal:  J Inflamm (Lond)       Date:  2016-06-04       Impact factor: 4.981

2.  Dual alternate access sites for the treatment of an ostial left common iliac artery chronic total occlusion.

Authors:  Mohan Satish; Sanjum S Sethi; Sahil Parikh; Philip Green; Justin Ratcliffe
Journal:  SAGE Open Med Case Rep       Date:  2020-06-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.